University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Early Phase 1

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)

First Posted Date: 2015-12-08

Last Posted Date: 2020-05-21

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 2

Registration Number: NCT02624258

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

CD123 Redirected Autologous T Cells for AML

Early Phase 1

Terminated

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Biological: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Drug: Cyclophosphamide

First Posted Date: 2015-12-07

Last Posted Date: 2017-10-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 7

Registration Number: NCT02623582

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Twitter and CV Health

Not Applicable

Completed

Conditions: Cardiovascular Disease
Hypertension

First Posted Date: 2015-12-04

Last Posted Date: 2019-01-24

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 611

Registration Number: NCT02622256

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Minimally Invasive Imagery With Indocyanine Green

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Indocyanine Green

First Posted Date: 2015-12-03

Last Posted Date: 2018-03-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 48

Registration Number: NCT02621268

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

SSRI Effects on Depression and Immunity in HIV/AIDS

Phase 4

Completed

Conditions: Depression
AIDS
HIV

Interventions: Drug: Escitalopram
Other: Placebo

First Posted Date: 2015-12-02

Last Posted Date: 2024-05-07

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 108

Registration Number: NCT02620150

Locations: 🇺🇸
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

Phase 2

Completed

Conditions: Opiate Dependence

Interventions: Drug: extended release naltrexone

First Posted Date: 2015-12-01

Last Posted Date: 2021-01-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 146

Registration Number: NCT02617628

Locations: 🇺🇸
Center on the Studies of Addiction, Philadelphia, Pennsylvania, United States

Multicomponent Yoga Intervention for Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Behavioral: Sudarshan Kriya Yoga

First Posted Date: 2015-11-30

Last Posted Date: 2015-12-08

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 25

Registration Number: NCT02616549

Locations: 🇺🇸
Mood & Anxiety Disorders Research and Treatment Program, Philadelphia, Pennsylvania, United States

Alpha Lipoic Acid in Geographic Atrophy

Phase 1

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: alpha lipoic acid
Drug: Placebo

First Posted Date: 2015-11-24

Last Posted Date: 2020-08-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 68

Registration Number: NCT02613572

Locations: 🇺🇸
Scheie Eye Institute of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Iowa Hospitals and Clinics, Department of Ophthalmology & Visual Sciences, Iowa City, Iowa, United States
🇺🇸
NJ Retina, Teaneck, New Jersey, United States

and more 2 locations

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Neoplasm
Metastatic Breast Cancer
Rb+ Breast Cancer

Interventions: Drug: [18F]FLT
Device: PET/CT
Drug: ribociclib
Drug: paclitaxel

First Posted Date: 2015-11-18

Last Posted Date: 2024-08-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT02608216

Locations: 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Intraoperative Imaging of Pulmonary Nodules by OTL38

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: OTL38

First Posted Date: 2015-11-11

Last Posted Date: 2022-06-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 262

Registration Number: NCT02602119

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy